Esophageal cancer is an aggressive, deadly cancer often caught in advanced stages. The likelihood of surviving for five years ...

Minimally invasive screening methods offer a more accessible, cost-effective way to detect Barrett’s esophagus early and help prevent esophageal cancer.

Q1 2025 Management View CEO Lishan Aklog stated that Lucid Diagnostics is “better positioned than ever to capitalize on EsoGuard’s really huge clinical and market opportunity,” emphasizing recent ...

Steve Dorsey has issued a stark warning for his fellow firefighters to check on one common undetected cancer symptom.

Lucid Diagnostics (NASDAQ:LUCD) reported positive data from a study showing that its EsoGuard esophageal DNA test can detect esophageal precancer in at-risk patients who don’t show typical ...

Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK, March 18, 2025 /PRNewswire/ -- Lucid ...

Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that it has submitted its complete clinical evidence package for its EsoGuard Esophageal DNA Test in support of a Request for ...

Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing For more information about Lucid, please visit www.luciddx.com and for more information about ...

Despite missing consensus revenue in the second quarter of 2024, Lucid Diagnostics saw a significant increase in EsoGuard test volume, indicating robust demand and growth potential. The 30% ...

Publication, which once again demonstrates strong EsoGuard performance in a screening population, completes Lucid's clinical evidence package for submission to formally seek Medicare coverage NEW ...